OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The Prognostic Value of Baseline Clinical and Radiologic Imaging Features in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab
Muhammad O. Awiwi, Khaled M. Elsayes, Yehia I. Mohamed, et al.
Journal of Hepatocellular Carcinoma (2022) Vol. Volume 9, pp. 913-927
Open Access | Times Cited: 6
Muhammad O. Awiwi, Khaled M. Elsayes, Yehia I. Mohamed, et al.
Journal of Hepatocellular Carcinoma (2022) Vol. Volume 9, pp. 913-927
Open Access | Times Cited: 6
Showing 6 citing articles:
Safety and Efficacy of Atezolizumab-Bevacizumab in Real World: The First Indian Experience
Anand V. Kulkarni, Vamsi Krishna, Karan Kumar, et al.
Journal of Clinical and Experimental Hepatology (2023) Vol. 13, Iss. 4, pp. 618-623
Open Access | Times Cited: 31
Anand V. Kulkarni, Vamsi Krishna, Karan Kumar, et al.
Journal of Clinical and Experimental Hepatology (2023) Vol. 13, Iss. 4, pp. 618-623
Open Access | Times Cited: 31
Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis
Anand V. Kulkarni, Harsh Vardhan Tevethia, Karan Kumar, et al.
EClinicalMedicine (2023) Vol. 63, pp. 102179-102179
Open Access | Times Cited: 26
Anand V. Kulkarni, Harsh Vardhan Tevethia, Karan Kumar, et al.
EClinicalMedicine (2023) Vol. 63, pp. 102179-102179
Open Access | Times Cited: 26
Clinical and Radiologic Predictors of Response to Atezolizumab-Bevacizumab in Advanced Hepatocellular Carcinoma
Se Jin Choi, Sung Won Chung, Jonggi Choi, et al.
Cancer Research and Treatment (2024) Vol. 56, Iss. 4, pp. 1219-1230
Open Access | Times Cited: 1
Se Jin Choi, Sung Won Chung, Jonggi Choi, et al.
Cancer Research and Treatment (2024) Vol. 56, Iss. 4, pp. 1219-1230
Open Access | Times Cited: 1
Objective Response and Progression-Free Survival Contribute to Prolong Overall Survival in Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma
Kazuto Tajiri, Kenichiro Tsukada, Yoshiharu Tokimitsu, et al.
Oncology (2023) Vol. 102, Iss. 2, pp. 131-140
Closed Access | Times Cited: 3
Kazuto Tajiri, Kenichiro Tsukada, Yoshiharu Tokimitsu, et al.
Oncology (2023) Vol. 102, Iss. 2, pp. 131-140
Closed Access | Times Cited: 3
Durable Stable Disease by Atezolizumab/Bevacizumab Can Provide Long-term Survival of Patients With Hepatocellular Carcinoma Lung Metastases
Toshihiko Motohara, Kensuke Yamamura, HIDEAKI MIYAMOTO, et al.
In Vivo (2023) Vol. 37, Iss. 5, pp. 2268-2275
Open Access | Times Cited: 1
Toshihiko Motohara, Kensuke Yamamura, HIDEAKI MIYAMOTO, et al.
In Vivo (2023) Vol. 37, Iss. 5, pp. 2268-2275
Open Access | Times Cited: 1
Platelet-to-lymphocyte ratio as a prognostic marker for advanced hepatocellular carcinoma treated with immune checkpoint inhibitors: Meta-analysis
Tong Zhao, Gulizere Aimaijiang, Yu Zhang, et al.
Research Square (Research Square) (2024)
Open Access
Tong Zhao, Gulizere Aimaijiang, Yu Zhang, et al.
Research Square (Research Square) (2024)
Open Access
